Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 14;78(24):2460-2470.
doi: 10.1016/j.jacc.2021.06.017.

Race, Ethnicity, Hypertension, and Heart Disease: JACC Focus Seminar 1/9

Affiliations
Free article
Review

Race, Ethnicity, Hypertension, and Heart Disease: JACC Focus Seminar 1/9

Modele O Ogunniyi et al. J Am Coll Cardiol. .
Free article

Abstract

Hypertension is the leading cause of cardiovascular morbidity and mortality globally. In the United States, the prevalence of hypertension (blood pressure ≥130/80 mm Hg) among adults is approximately 45%. Racial/ethnic disparities in hypertension prevalence are well documented, especially among Black adults who are disproportionately affected and have one of the highest rates of hypertension globally. Hypertension control remains a persistent public health crisis. Recently published data indicate suboptimal hypertension control rates, particularly for racial/ethnic minority groups in the United States. This requires urgent action because of the significant health care burden from cardiovascular- and stroke-related morbidity and mortality. This clinical review delineates racial/ethnic disparities in the epidemiology of hypertension, and the impact of social determinants of health on the quality of cardiovascular care and outcomes. Clinical practice guideline recommendations and various national programs targeted toward hypertension control and proposed solutions to eliminate these disparities are discussed.

Keywords: disparities; ethnicity; hypertension; race; social determinants of health.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Ogunniyi has received institutional research grants from AstraZeneca, Boehringer Ingelheim, and Zoll; and has served as a consultant on the Advisory Board for Pfizer. Dr Ferdinand has received support from Novartis and Medtronic. Dr Commodore-Mensah has reported that she has no relationships relevant to the contents of this paper to disclose.

LinkOut - more resources